Highest-materiality recent filing
CNS Pharma raises ~$22.5M in private placement at $2.30/sh; board change
Gross proceeds ~$22.5M from sale of 650K shares at $2.30/sh and pre-funded warrants for 9.14M shares at $2.299/warrant.
CNS Pharmaceuticals appoints Lynne Kelley as CMO; former CMO Sandra Silberman departs with severance
Lynne Kelley appointed CMO effective March 2, 2026; base salary $450K, target bonus 40%.
CNS Pharmaceuticals appoints Steve O'Loughlin as CFO; current CFO Downs moves to SVP Finance
Steve O'Loughlin appointed CFO effective March 2, 2026; base salary $450,000, target bonus 40% of base.
CNS Pharmaceuticals appoints Rami Levin as CEO effective January 1, 2026; John Climaco resigns
Rami Levin becomes CEO and President effective Jan 1, 2026; base salary $580,000, target bonus 50% of base, initial RSU grant of 19,000 shares.
Authorized common stock increased from 25M to 300M shares; preferred from 416,667 to 5M shares.
CNS Pharmaceuticals announces 1-for-12 reverse stock split effective July 22, 2025
Reverse split reduces outstanding shares from ~6.36M pre-split to ~529,829 post-split.
CNS Pharmaceuticals raises ~$5.0M in public offering of stock and warrants
Offering of 325,000 shares, 3,627,570 pre-funded warrants, and 3,952,570 common warrants.
CNS Pharmaceuticals regains Nasdaq compliance; subject to one-year monitoring period
Nasdaq letter dated March 31, 2025 confirms regained compliance with $1.00 bid price rule.
CNS Pharmaceuticals ups ATM sales capacity to $43.5M from $30.2M; $23.75M raised so far
Company increased aggregate sales price under A.G.P. Sales Agreement to $43.5M on March 20, 2025.
CNS Pharmaceuticals announces 1-for-50 reverse stock split effective Feb 21, 2025
Reverse stock split at 1-for-50 ratio effective Feb 21, 2025; shares outstanding reduced from ~136.93M to ~2.74M.
CNS Pharmaceuticals sold 17.5M shares via ATM; shares outstanding now 74.96M
Sold 17,475,827 shares under at-the-market agreement since last 10-Q (Sept 30, 2024).
Company received Nasdaq deficiency notice on Sept 12, 2024 for bid price below $1.00 for 30 consecutive days.
Gross proceeds ~$3M from sale of 3.7M common shares and pre-funded warrants for 13.9M shares at $0.17/share.
CNS Pharma faces Nasdaq delisting for bid price deficiency; hearing Nov 5
Received Nasdaq notice on Sept 12, 2024, for failing minimum $1.00 bid price for 30 consecutive days.
CNS Pharma receives Nasdaq minimum bid deficiency; ineligible for cure due to reverse splits
Nasdaq notified CNS Pharma on Sept 12, 2024 that common stock failed to maintain $1.00 minimum bid for 30 consecutive days.
CNS Pharma regains Nasdaq compliance; subject to one-year Mandatory Panel Monitor
On Sep 10, 2024, Nasdaq confirmed CNS Pharma has demonstrated compliance with the $2.5M stockholders' equity requirement; delisting matter closed.
CNS Pharmaceuticals regains Nasdaq equity compliance after $9.9M share sale
Shareholders' equity exceeds $5.0M, above Nasdaq's $2.5M minimum for continued listing.
CNS Pharmaceuticals in-licenses TPI 287 from Cortice for brain cancer treatment
CNS Pharmaceuticals entered an exclusive license agreement with Cortice Biosciences for TPI 287, a blood-brain barrier permeable abeotaxane, covering U.S., Canada, Mexico, and Japan.
CNS Pharma boosts ATM equity facility from $5.2M to $30.2M; $5.19M already sold
On July 30, 2024, CNS Pharmaceuticals increased the aggregate sales price under its ATM agreement to $25M, for a total of $30.2M including original $5.2M.
CNS Pharma enters $5.2M ATM offering with A.G.P.; warrants repriced
Entered Sales Agreement with A.G.P. for at-the-market offering of up to $5.2M common stock; commission 3.0%.
CNS Pharmaceuticals gets final Nasdaq extension to Aug 12 for equity compliance
Nasdaq Panel granted extension until August 12, 2024 to meet $2.5M stockholders' equity requirement.
CNS Pharmaceuticals raises ~$1.39M in registered direct offering and private placement
Priced 568,000 common shares plus warrants for 568,000 shares at $2.45 per unit, gross proceeds ~$1.39M.
CNS Pharmaceuticals prices $1.37M registered direct offering and private placement
Offering of 366,000 shares (or pre-funded warrants) at $3.75/share, with common warrants exercisable at $3.62.
1-for-50 reverse stock split effective 4:01 PM ET June 4, 2024; trading on split-adjusted basis from June 5, 2024 under symbol CNSP.
Nasdaq Panel grants CNS Pharmaceuticals extension to July 15, 2024 to regain listing compliance
Hearing held April 18, 2024; panel grants extension until July 15, 2024.
Authorized common shares increased from 75M to 300M; 3.5M shares added to 2020 Equity Plan (total 4,345,800).
CNS Pharma FY2023 net loss $18.9M; Berubicin DSMB OK, enrollment done, topline due H1 2025
Net loss $18.9M vs $15.3M in 2022; R&D expenses $14.1M (up from $9.3M) on Berubicin trial costs.
CNS Pharma receives Nasdaq bid-price deficiency notice; board committee changes
On Feb 27, 2024, Nasdaq notified CNS Pharma common stock bid price closed below $1.00 for 30 consecutive business days, violating Rule 5550(a)(2).
CNS Pharmaceuticals receives Nasdaq delisting notice over equity shortfall; will request hearing
Nasdaq notified CNSP on Feb 14, 2024, that it failed to meet minimum $2.5M stockholders' equity requirement after extension expired.
CNS Pharma raises $3.7M in $0.30/unit offering; appoints Amy Mahery to board
Offering of 2.2M shares, 11.1M pre-funded warrants, and 26.7M Series A & B warrants at $0.30 per unit.
DSMB recommends CNS Pharma's Berubicin trial continue unmodified after interim analysis
DSMB recommended continuation of Berubicin vs. Lomustine Phase 2/3 trial in recurrent GBM based on comparable overall survival.
CNS Pharma Q3 net loss $4.5M; Berubicin enrollment at 239, interim data Dec 2023
Net loss of $4.5M vs $3.4M in Q3 2022; R&D expenses rose to $3.4M on clinical progress.
CNS Pharma raises ~$2.4M via warrant exercise; issues new inducement warrants for 3.76M shares
Holder exercised Existing Warrants for 1,878,000 shares at reduced exercise price of $1.28 per share.
CNS Pharma receives Nasdaq delisting notice for failure to meet $2.5M equity requirement
Nasdaq notified CNS Pharma on Aug 17, 2023 of non-compliance with $2.5M stockholders' equity minimum (Rule 5550(b)(1)).
On May 4, 2026, Jerzy (George) Gumulka resigned as a member of the Company’s Board of Directors (the “Board”) . Mr. Gumulka’s resignation from the Board was not a result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
On May 4, 2026, the Board agreed to appoint Michal Fisher as an independent member of the Company’s Board.
As previously reported, on January 17, 2024, the Company’s Board of Directors (the “Board”) agreed to appoint Amy Mahery as an independent member of the Company’s Board effective upon the completion of the Company’s financing.
On January 17, 2024, the Board of Directors of CNS Pharmaceuticals, Inc. (the “Company”) agreed to appoint Amy Mahery as an independent member of the Company’s Board of Directors effective upon the completion of the Company’s financing.
On May 3, 2023, the Board of Directors of CNS Pharmaceuticals, Inc. (the “Company”) appointed Bettina M. Cockroft, M.D., M.B.A as an independent member of the Company’s Board of Directors effective on such date.
On December 30, 2022, the Board of Directors of CNS Pharmaceuticals, Inc. (the “Company”) appointed Faith Charles as an independent member of the Company’s Board of Directors and as Chairperson of the Board of Directors, effective on such date.
Max materiality 0.85 · Median 0.65 · Most common event other_material